Australia markets closed

INmune Bio, Inc. (INMB)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
10.84+0.22 (+2.07%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 197.32M
Enterprise value 171.91M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.26k
Price/book (mrq)5.17
Enterprise value/revenue 1.11k
Enterprise value/EBITDA -5.78

Trading information

Stock price history

Beta (5Y monthly) 1.95
52-week change 349.52%
S&P500 52-week change 321.08%
52-week high 314.74
52-week low 36.50
50-day moving average 311.44
200-day moving average 39.62

Share statistics

Avg vol (3-month) 3102.68k
Avg vol (10-day) 3173.09k
Shares outstanding 518.2M
Implied shares outstanding 618.2M
Float 811.72M
% held by insiders 133.79%
% held by institutions 113.25%
Shares short (15 Apr 2024) 41.5M
Short ratio (15 Apr 2024) 414.76
Short % of float (15 Apr 2024) 412.60%
Short % of shares outstanding (15 Apr 2024) 48.25%
Shares short (prior month 15 Mar 2024) 41.44M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-29,925.00%

Management effectiveness

Return on assets (ttm)-26.79%
Return on equity (ttm)-61.09%

Income statement

Revenue (ttm)155k
Revenue per share (ttm)0.01
Quarterly revenue growth (yoy)-71.10%
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-30.01M
Diluted EPS (ttm)-1.67
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35.85M
Total cash per share (mrq)1.99
Total debt (mrq)10.44M
Total debt/equity (mrq)27.37%
Current ratio (mrq)2.16
Book value per share (mrq)2.08

Cash flow statement

Operating cash flow (ttm)-11.98M
Levered free cash flow (ttm)-1.4M